LONGEVA.

MOTS-c dosing schedule

mots-c dosage

> Updated:

MOTS-c (preset)

Calculate the MOTS-c dose

The calculator is already set up for MOTS-c — adjust the dose or diluent volume for your vial.

Open calculator

In short

MOTS-c is a mitochondrial-derived peptide. No validated human regimen has been established: there are no human interventional data, and an effect has been shown only in mice – in the study by Reynolds and colleagues (Nature Communications, 2021), administration three times a week improved endurance in old animals. The peptide's half-life in blood is measured in minutes, so protocol schedules use frequent small administrations: 2.5–5 mg start, 5 mg standard regimen, up to 10 mg upper range, 2–3 times a week, over a 4–8 week cycle.

Human dosing

MOTS-c dosing in protocols is set individually for each experiment, so the schedule below is a reference point drawn from published data, not a standard for self-administration.

Period / conditionDoseEscalation
Start2.5–5 mg, 3x weeklyStarting dose
Standard regimen5 mg, 2–3x weeklyIncrease if needed
Upper range (4–8-week cycle)10 mg, 2–3x weeklyMaximum in this schedule
Practical dosing and effect details

Protocols set the MOTS-c dose around a specific experimental goal, and published literature gives a clear example of how administration frequency ties to an observed effect. In a study by Reynolds and colleagues (Nature Communications, 2021), MOTS-c administration improved physical performance in mice across three age groups: young (2 mo.), middle-aged (12 mo.), and old (22 mo.). In a separate part of the same study, old mice (23.5 mo.) received the peptide intermittently, three times a week; this raised endurance and health measures in the aged animals. These results come from mice only and do not prove an effect in humans.

The schedule on this page (2.5–5 mg starting dose, 5 mg standard, 10 mg upper range) reflects the same logic of frequent, short administration rather than one large dose: the peptide's half-life in blood is measured in minutes, so infrequent injections poorly sustain its level across the observation window.

This is reference information on regimens from published sources, not a medical recommendation.

Frequently asked questions

What is MOTS-c? A mitochondrial-derived peptide. In studies and protocols it is administered subcutaneously; this page compiles the published regimens and the animal data.

Has MOTS-c been shown to work in humans? No. There are no human interventional data; improved physical performance and endurance have been shown only in mice across three age groups (Reynolds and colleagues, Nature Communications, 2021), and those results do not transfer to humans.

Why is MOTS-c administered 2–3 times a week? The peptide's half-life in blood is measured in minutes, so infrequent injections poorly sustain its level; hence the logic of frequent short administrations rather than one large dose.

Does MOTS-c come as a nasal spray? The sources behind this page describe subcutaneous administration only; the published regimens compiled here do not include nasal forms.

Is there a separate MOTS-c dose for women? The table on this page does not split doses by sex: they are set around the goal of each protocol. No validated regimen for humans – women or men – has been established.

How to reconstitute

An example reconstitution for convenient dosing. The exact ratios depend on your vial. For research reference only — not medical guidance.

  1. 1Add the diluentUse bacteriostatic water. Example: 2 ml into a 10 mg vial.MOTS-c10 mg+ 2 mlDiluent
  2. 2Get the concentrationExample: 10 mg in 2 ml =MOTS-c5 mg/ml(5,000 mcg/ml)
  3. 3Work out the volume per doseFor example, for a 2.5 mg dose:2.5 mg = 0.5 ml= 50 u. (U-100)

This is only an example calculation. You can use a different diluent volume — plug your own numbers into the calculator. Open calculator →

Research protocols

MOTS-c: reference regimens

MOTS-c is a mitochondrial-derived peptide administered subcutaneously (injection) in studies and protocols.

More scientific background in the MOTS-c monograph

Notes and safety

  • • MOTS-c is a research peptide. Human safety and efficacy data are limited.
  • • The regimens shown are based on publications and research protocols, not clinical recommendations.
  • • Individual reactions may vary. Published protocols typically start dosing at the lower end of the reported range.
  • • Not recommended for use with chronic illness, pregnancy, or breastfeeding.
  • • This information is for educational purposes and is not medical advice.
This is not medical advice — research information only.This material is not intended for diagnosis, treatment or prevention of disease.